Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

Brunstein CG, (2016) Blood, (Link to Abstract)


In this article, the authors examined the rate of GVHD in eleven adult patients undergoing double umbilical cord blood (UCB) stem cell transplantation receiving additional UCB-derived T regulatory cells on day +1 from a third UCB graft 4-6/6 matched. The rate of GVHD was compared to contemporary controls (n=22). The authors found low grade II-I


* GVHD on day 100 of 9% in the treatment cohort compared to 45% in controls (p=0.05). At 1 year there were no patients with cGVHD in the treatment group compared to 14% in controls (no statistical comparison provided). No differences in treatment-mortality or relapse were seen.


* In double UCB-HSCT of adult patients with hematological malignancies, the transfusion of T reg from a third UCB graft resulted in low acute and chronic GVHD rates although the numbers in this study were small and therefore definite conclusions cannot be drawn. It would be interested to see a similar approach in children.